Najat Khan is a distinguished figure in the pharmaceutical industry, currently serving as the Chief R&D and Chief Commercial Officer at Recursion Pharmaceuticals Inc. With a robust background in drug discovery and development, Khan has been instrumental in steering the company's research and commercialization strategies. She joined Recursion with an extensive track record, having previously held key positions at major pharmaceutical companies such as Merck and Pfizer. Her expertise in oncology and immuno-oncology has been pivotal in advancing Recursion's mission to accelerate drug discovery through the use of artificial intelligence and machine learning. At Recursion Pharmaceuticals, Khan oversees the entire spectrum of the company's R&D efforts, from early-stage research to late-stage clinical development. Her role as Chief R&D Officer involves managing a diverse team of scientists and researchers who work collaboratively to harness the power of Recursion's proprietary technology platform. As Chief Commercial Officer, she is responsible for developing and executing the company's go-to-market strategies, ensuring that innovative therapies reach patients efficiently. Under her leadership, Recursion has made significant strides in expanding its pipeline and forging strategic partnerships, solidifying its position as a leader in tech-driven drug discovery. Khan's contributions to the field have been widely recognized, and her strategic vision has been crucial in navigating the complex landscape of pharmaceutical innovation. Her ability to integrate advanced technologies with traditional drug development processes has not only enhanced Recursion's capabilities but also set new standards in the industry. Khan's dual role at Recursion exemplifies her commitment to transforming healthcare through cutting-edge research and effective commercialization, ultimately aiming to improve patient outcomes on a global scale.